GlassScriptPhysician profile
Stephen J Hornak
NPI 1871685990
$6,269.52
in general payments reported to CMS, 2019-2025
39 companies · $1,038 in 2025
The $1,038 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $537 · 2020: $587 · 2021: $1,026 · 2022: $895 · 2023: $1,191 · 2024: $995 · 2025: $1,038.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,225.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,224.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $953.26 | 2019-2025 | Farxiga, Brilinta, Lokelma |
| Novartis Pharmaceuticals Corporation | $928.15 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $692.10 | 2019-2024 | Xarelto |
| Amgen INC. | $468.30 | 2019-2025 | Repatha |
| Pfizer INC. | $465.51 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $265.24 | 2021-2024 | Eliquis, Camzyos |
| Arbor Pharmaceuticals, INC. | $228.18 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $214.65 | 2019-2025 | Jardiance |
| Sanofi-Aventis U.S. LLC | $195.63 | 2019-2024 | |
| Amarin Pharma, INC. | $180.35 | 2020-2022 | |
| Boston Scientific Corporation | $167.37 | 2019-2023 | Watchman Access System |
| Merck Sharp & Dohme LLC | $163.90 | 2022-2025 | Verquvo, Capvaxive |
| Abbott Laboratories | $145.83 | 2020-2025 | Aveir, Thoratec Heartmate 3 Lvas Implant Kit |
| Scpharmaceuticals INC. | $136.35 | 2023-2025 | |
| Novo Nordisk INC | $103.79 | 2021-2025 | Ozempic |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Hornak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.